Literature DB >> 30976660

Family History of Breast Cancer Associated with Breast Cancer in Survivors of Hodgkin Lymphoma.

Sarah Colonna1,2,3, Karen Curtin1,2, Eric Johnson1,2, Wendy Kohlmann1, Jennifer Wright1,4, Anne Kirchhoff4, Sean Tavtigian1, Joshua Schiffman1,4.   

Abstract

INTRODUCTION: Advances in treatments for Hodgkin Lymphoma (HL) have significantly increased survival of childhood and adult patients; however, the leading cause of death in HL survivors is due to secondary malignancy following HL treatment [1,2]. Among women treated for HL, breast cancer (BC) is the most common secondary malignancy [3]. We explored if an association exists between HL and BC exists within families.
METHODS: Utilizing the Utah Population Database and the Utah Cancer Registry, we identified 988 women with HL, and no history of BC prior to HL, diagnosed in Utah from 1966-2014. We examined if women with HL were at greater risk of developing BC based on the presence or absence of family history of BC. We also examined the familial recurrence risk of BC among female FDRs of women with HL and BC using Cox regression methods. RESULT: Among 988 female HL patients, 42 (4.3%) were diagnosed with subsequent BC while among 9,876 matched controls, 280 controls (2.8%) were diagnosed with BC from 1966-2014 (P < 0.05). We observed a significant 3-fold increased risk of BC in the first-degree relatives (parent, full sibling, or child of patient) of female HL patients with subsequent BC, compared to FDR in controls (HR = 2.8, 95%CI 1.4-5.6; P = 0.005). Female HL patients who had a family history of BC were significantly more likely to develop BC, compared to HL patients with no history of BC among relatives (HR = 3.3, 95%CI 1.6-7.1; P = 0.002).
CONCLUSION: Women with HL and a family history of BC are at even higher than anticipated risk of BC, as are their female relatives. Obtaining a thorough family history for a woman preparing to undergo therapy for HL is important for treatment decisions for HL and maintaining an up to date family history over time is also important for the management of a woman's ongoing cancer risks and her surveillance strategy following survival of HL.

Entities:  

Keywords:  Breast cancer; Cancer genetics; Epidemiology; Hodgkin lymphoma; Survivorship

Year:  2019        PMID: 30976660     DOI: 10.23937/2378-3419/1410107

Source DB:  PubMed          Journal:  Int J Cancer Clin Res        ISSN: 2378-3419


  35 in total

1.  Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma.

Authors:  Lois B Travis; Deirdre Hill; Graça M Dores; Mary Gospodarowicz; Flora E van Leeuwen; Eric Holowaty; Bengt Glimelius; Michael Andersson; Eero Pukkala; Charles F Lynch; David Pee; Susan A Smith; Mars B Van't Veer; Timo Joensuu; Hans Storm; Marilyn Stovall; John D Boice; Ethel Gilbert; Mitchell H Gail
Journal:  J Natl Cancer Inst       Date:  2005-10-05       Impact factor: 13.506

2.  A cohort study of cancer risk in relation to family histories of cancer in the Utah population database.

Authors:  Richard A Kerber; Elizabeth O'Brien
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

Review 3.  Breast cancer risk following irradiation for Hodgkin's disease.

Authors:  M Clemons; L Loijens; P Goss
Journal:  Cancer Treat Rev       Date:  2000-08       Impact factor: 12.111

4.  Familial aggregation of juvenile idiopathic arthritis.

Authors:  Sampath Prahalad; Elizabeth O'brien; Alison M Fraser; Richard A Kerber; Geraldine P Mineau; David Pratt; David Donaldson; Michael J Bamshad; John Bohnsack
Journal:  Arthritis Rheum       Date:  2004-12

5.  Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors.

Authors:  G Sanna; K Lorizzo; N Rotmensz; V Bagnardi; S Cinieri; M Colleoni; F Nolè; A Goldhirsch
Journal:  Ann Oncol       Date:  2006-11-06       Impact factor: 32.976

6.  Breast cancer after mantle irradiation for Hodgkin's disease: correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2.

Authors:  D K Gaffney; J Hemmersmeier; J Holden; J Marshall; L M Smith; V Avizonis; T Tran; S L Neuhausen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-02-01       Impact factor: 7.038

7.  Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years.

Authors:  Graça M Dores; Catherine Metayer; Rochelle E Curtis; Charles F Lynch; E Aileen Clarke; Bengt Glimelius; Hans Storm; Eero Pukkala; Flora E van Leeuwen; Eric J Holowaty; Michael Andersson; Tom Wiklund; Timo Joensuu; Mars B van't Veer; Marilyn Stovall; Mary Gospodarowicz; Lois B Travis
Journal:  J Clin Oncol       Date:  2002-08-15       Impact factor: 44.544

8.  Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors.

Authors:  Andrea K Ng; M V Patricia Bernardo; Edie Weller; Kendall Backstrand; Barbara Silver; Karen C Marcus; Nancy J Tarbell; Mary Ann Stevenson; Jonathan W Friedberg; Peter M Mauch
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

9.  Long-term cause-specific mortality of patients treated for Hodgkin's disease.

Authors:  Berthe M P Aleman; Alexandra W van den Belt-Dusebout; Willem J Klokman; Mars B Van't Veer; Harry Bartelink; Flora E van Leeuwen
Journal:  J Clin Oncol       Date:  2003-07-28       Impact factor: 44.544

10.  Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease.

Authors:  Lois B Travis; Deirdre A Hill; Graça M Dores; Mary Gospodarowicz; Flora E van Leeuwen; Eric Holowaty; Bengt Glimelius; Michael Andersson; Tom Wiklund; Charles F Lynch; Mars B Van't Veer; Ingrid Glimelius; Hans Storm; Eero Pukkala; Marilyn Stovall; Rochelle Curtis; John D Boice; Ethel Gilbert
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

View more
  2 in total

1.  Childhood central nervous system tumors and leukemia: Incidence and familial risk. A comparative population-based study in Utah and Norway.

Authors:  Ruby Del Risco Kollerud; Lisa A Cannon-Albright; Hege S Haugnes; Ellen Ruud; Magne Thoresen; Per Nafstad; Karl Gerhard Blaasaas; Øyvind Naess; Bjørgulf Claussen
Journal:  Pediatr Blood Cancer       Date:  2020-05-21       Impact factor: 3.167

Review 2.  A Review of Modifiable Risk Factors in Young Women for the Prevention of Breast Cancer.

Authors:  Alex A Daly; Rachel Rolph; Ramsey I Cutress; Ellen R Copson
Journal:  Breast Cancer (Dove Med Press)       Date:  2021-04-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.